Literature DB >> 2867325

The prevention of breast cancer.

J Cuzick, D Y Wang, R D Bulbrook.   

Abstract

The case for treating women at high risk of breast cancer with the anti-oestrogen tamoxifen is presented. This is a logical extension of a screening programme and is scientifically based on the effectiveness of tamoxifen in established disease, the relation between free oestradiol (and other hormone-related factors) to the risk of breast cancer, and the lack of side-effects from tamoxifen treatment. Choice of a high-risk group is critical; a specific trial protocol is outlined.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2867325     DOI： 10.1016/s0140-6736(86)90729-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  19 in total

1.  Ovarian status influences the skeletal effects of tamoxifen in adult rats.

Authors:  J D Sibonga; G L Evans; E R Hauck; N H Bell; R T Turner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women.

Authors:  M Stomati; B Hartmann; A Spinetti; D Mailand; S Rubino; A Albrecht; J Huber; F Petraglia; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

Review 3.  Progress in understanding breast cancer: epidemiological and biological interactions.

Authors:  P Boyle; R Leake
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

4.  Oestrogen receptor activity in intraduct and invasive breast carcinomas.

Authors:  R A Hawkins; A L Tesdale; W A Ferguson; J J Going
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

5.  Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors.

Authors:  Partha Pratim Roy; Kunal Roy
Journal:  J Mol Model       Date:  2010-03-01       Impact factor: 1.810

Review 6.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.

Authors:  T Engan; J Krane; D C Johannessen; P E Lønning; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 8.  Antiestrogen action of progesterone in breast tissue.

Authors:  P Mauvais-Jarvis; F Kuttenn; A Gompel
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

9.  Chemoprevention of breast cancer.

Authors:  T J Powles; J R Hardy; S E Ashley; D Cosgrove; J B Davey; M Dowsett; A McKinna; A G Nash; S K Rundle; H D Sinnett
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

10.  The Royal Marsden Hospital pilot tamoxifen chemoprevention trial.

Authors:  T J Powles; A L Jones; S E Ashley; M E O'Brien; V A Tidy; J Treleavan; D Cosgrove; A G Nash; N Sacks; M Baum
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.